Literature DB >> 961459

Controlled trial of penfluridol and thiothixene in the maintenance treatment of chronic schizophrenic syndromes.

L Jacobsson, L Von Knorring, B Mattsson, C Perris, W Rapp, B Edenius, B Kettner, K E Magnusson, P Villemoes.   

Abstract

In a controlled trial of penfluridol and thiothixene as maintenance drugs in patients with chronic schizophrenic syndromes, some improvement over previous neuroleptics was seen with both drugs. This improvement was mainly evident in variables concerned with participation in social activities as assessed with the S-scale and by ward behaviour. The drug dosages necessary were very low and gave few and easily manageable side-effects. There was no significant difference between penfluridol and thiothixene. Penfluridol has the clear practical advantage of being the only long-acting drug for oral administration so far available.

Entities:  

Mesh:

Substances:

Year:  1976        PMID: 961459     DOI: 10.1111/j.1600-0447.1976.tb00103.x

Source DB:  PubMed          Journal:  Acta Psychiatr Scand        ISSN: 0001-690X            Impact factor:   6.392


  4 in total

1.  Monoamine metabolite levels in cerebrospinal fluid of psychotic women treated with melperone or thiothixene.

Authors:  L Bjerkenstedt; B Gullberg; C Härnryd; G Sedvall
Journal:  Arch Psychiatr Nervenkr (1970)       Date:  1977-10-11

2.  Effects of melperone and thiothixene on prolactin levels in cerebrospinal fluid and plasma of psychotic women.

Authors:  L Bjerkenstedt; P Eneroth; C Härnryd; G Sedvall
Journal:  Arch Psychiatr Nervenkr (1970)       Date:  1977-12-28

3.  A double-blind comparison of melperone and thiothixene in psychotic women using a new rating scale, the CPRS.

Authors:  L Bjerkenstedt; C Härnryd; V Grimm; B Gullberg; G Sedvall
Journal:  Arch Psychiatr Nervenkr (1970)       Date:  1978-12-14

4.  Correlation of thiothixene serum levels and age.

Authors:  J A Yesavage; C A Holman; R Cohn
Journal:  Psychopharmacology (Berl)       Date:  1981       Impact factor: 4.530

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.